KalVista Pharmaceuticals, Inc. (KALV)
NASDAQ: KALV · Real-Time Price · USD
16.25
+0.04 (0.25%)
Mar 6, 2026, 2:53 PM EST - Market open
KalVista Pharmaceuticals Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for KalVista Pharmaceuticals stock have an average target of 30, with a low estimate of 20 and a high estimate of 37. The average target predicts an increase of 84.62% from the current stock price of 16.25.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jan 9, 2026.
Analyst Ratings
The average analyst rating for KalVista Pharmaceuticals stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 3 | 3 |
| Buy | 3 | 3 | 3 | 3 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $27 → $37 | Strong Buy | Maintains | $27 → $37 | +127.69% | Jan 9, 2026 |
| Needham | Needham | Strong Buy Maintains $32 → $35 | Strong Buy | Maintains | $32 → $35 | +115.38% | Jan 9, 2026 |
| Needham | Needham | Strong Buy Maintains $28 → $32 | Strong Buy | Maintains | $28 → $32 | +96.92% | Jan 6, 2026 |
| Needham | Needham | Strong Buy Reiterates $28 | Strong Buy | Reiterates | $28 | +72.31% | Dec 4, 2025 |
| Citizens | Citizens | Buy Maintains $29 → $28 | Buy | Maintains | $29 → $28 | +72.31% | Nov 11, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
160.19M
EPS This Year
-3.61
from -3.69
EPS Next Year
-3.09
from -3.61
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | 258.5M | ||||
| Avg | n/a | 160.2M | ||||
| Low | n/a | 33.0M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -3.51 | -2.52 | ||||
| Avg | -3.61 | -3.09 | ||||
| Low | -3.71 | -3.53 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.